Securian Asset Management Inc. Has $1.03 Million Holdings in IQVIA Holdings Inc. $IQV

Securian Asset Management Inc. trimmed its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 44.0% during the fourth quarter, Holdings Channel.com reports. The firm owned 4,571 shares of the medical research company’s stock after selling 3,585 shares during the period. Securian Asset Management Inc.’s holdings in IQVIA were worth $1,030,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Ameliora Wealth Management Ltd. acquired a new position in shares of IQVIA during the fourth quarter valued at about $25,000. Physician Wealth Advisors Inc. boosted its stake in IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 134 shares during the last quarter. International Assets Investment Management LLC purchased a new stake in shares of IQVIA in the fourth quarter worth approximately $27,000. Westside Investment Management Inc. lifted its holdings in shares of IQVIA by 219.6% in the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 101 shares in the last quarter. Finally, Measured Wealth Private Client Group LLC bought a new stake in IQVIA during the third quarter worth $30,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Citigroup cut their price objective on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a report on Friday, February 6th. Weiss Ratings downgraded shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Royal Bank Of Canada assumed coverage on IQVIA in a research note on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 target price on the stock. Morgan Stanley set a $225.00 price objective on IQVIA in a research report on Thursday, May 7th. Finally, Mizuho set a $215.00 target price on IQVIA in a research note on Monday, February 23rd. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, IQVIA currently has a consensus rating of “Buy” and an average price target of $225.69.

IQVIA Stock Up 0.7%

IQV opened at $174.70 on Wednesday. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $247.04. The company has a market cap of $29.16 billion, a PE ratio of 21.65, a price-to-earnings-growth ratio of 1.67 and a beta of 1.18. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The company has a 50 day moving average of $170.43 and a 200 day moving average of $200.08.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.83 by $0.07. The firm had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business’s quarterly revenue was up 8.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, sell-side analysts expect that IQVIA Holdings Inc. will post 11.52 EPS for the current year.

IQVIA declared that its board has approved a share repurchase plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.